Ultraviolet C light efficiently inactivates nonenveloped hepatitis A virus and feline calicivirus in platelet concentrates. Issue 11 (28th September 2018)

• Record Type: Journal Article
• Authors: Gravemann, Ute; Handke, Wiebke; Lambrecht, Bernd; Schmidt, Jörg‐Peter; Müller, Thomas H.; Seltsam, Axel
• Is Part Of: Transfusion. Volume 58:Issue 11(2018)
• Page Start: 2669
• Page End: 2674
• Publication Date: 2018-09-28
• Subjects: Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.14957
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract : BACKGROUND: Nonenveloped transfusion‐transmissible viruses such as hepatitis A virus (HAV) and hepatitis E virus (HEV) are resistant to many of the common virus inactivation procedures for blood products. This study investigated the pathogen inactivation (PI) efficacy of the THERAFLEX UV‐Platelets system against two nonenveloped viruses: HAV and feline calicivirus (FCV), in platelet concentrates (PCs). STUDY DESIGN AND METHODS: PCs in additive solution were spiked with high titers of cell culture–derived HAV and FCV, and treated with ultraviolet C at various doses. Pre‐ and posttreatment samples were taken and the level of viral infectivity determined at each dose. For some samples, large‐volume plating was performed to improve the detection limit of the virus assay. RESULTS: THERAFLEX UV‐Platelets reduced HAV titers in PCs to the limit of detection, resulting in a virus reduction factor of greater than 4.2 log steps, and reduced FCV infectivity in PCs by 3.0 ± 0.2 log steps. CONCLUSIONS: THERAFLEX UV‐Platelets effectively inactivates HAV and FCV in platelet units.